Understanding HHRH and NPHLOP1: When Stones and Bone Loss Meet
At a Glance
HHRH and NPHLOP1 are inherited disorders in which the kidneys lose too much phosphate. This can raise active vitamin D and urine calcium, leading to kidney stones, kidney calcification, and weak or softened bones; prescribed phosphate is the usual treatment for significant phosphate loss.
If you have spent years dealing with recurrent kidney stones, “thin bones,” or unexplained fractures, finally hearing the name Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) or NPHLOP1 can be both a relief and a source of confusion. These are rare genetic conditions that change how your kidneys handle minerals, leading to a cascade of issues that affect your entire body [1][2].
Because these conditions are rare—one published estimate places the prevalence of classic HHRH at roughly 1 in 250,000 people—many doctors may never have seen a case in their entire careers [1]. In adults, the diagnosis is frequently missed because the symptoms look like more common problems, such as “idiopathic” (unexplained) kidney stones or standard osteoporosis [3].
Why This Was Likely Missed
The road to a diagnosis for HHRH or NPHLOP1 is often long and frustrating. Adults may be told they simply have “stone-forming” genes or that their low bone density is just early-onset osteoporosis. There are several reasons why these conditions stay hidden:
- The Overlooked Mineral: Routine blood tests often focus on calcium, but serum phosphate is not always included. Without checking phosphate, the core problem remains invisible [4].
- The Osteoporosis Trap: A DXA scan (a common bone density test) can show that your bones are thin, but it cannot tell the difference between typical osteoporosis and osteomalacia (softening of the bones caused by mineral loss) [5].
- Symptom Overlap: Doctors often treat kidney stones by focusing on calcium in the urine. However, in HHRH, the high urine calcium is actually a side effect of a phosphate problem [6].
The Core Problem: The Phosphate Cascade
In a healthy body, the kidneys act like a filter that recaptures important minerals. In HHRH and NPHLOP1, the transporters in the kidney (NPT2c and NPT2a) do not work correctly [2][7].
This creates a chain reaction:
- Phosphate Wasting: Your kidneys let too much phosphate leak into your urine, causing low levels in your blood (hypophosphatemia) [8].
- Active Vitamin D Increase: To compensate, your body ramps up production of 1,25-dihydroxyvitamin D (the active form of vitamin D) [6].
- Calcium Excretion: This high active vitamin D forces your gut to absorb extra calcium. While your blood calcium typically remains normal, your kidneys must flush out the excess. This leads to very high calcium in your urine (hypercalciuria) [6][9].
- Stones and Weak Bones: The constant high levels of calcium in your urine lead to nephrolithiasis (kidney stones) and nephrocalcinosis (calcium deposits in the kidney tissue). Meanwhile, your bones become starved of the minerals they need [8][9].
Which Category Are You In?
While HHRH, NPHLOP1, and carrier states are related, they are not the same condition. Understanding your exact genetics helps predict symptoms and guide family testing [9][10][2].
| Condition | Gene & Inheritance | Typical Presentation |
|---|---|---|
| Classic HHRH | Biallelic SLC34A3 (Two mutated copies) | Childhood rickets, bone pain, short stature, highly penetrant risk of kidney stones and nephrocalcinosis. |
| SLC34A3 Carrier | Monoallelic SLC34A3 (One mutated copy) | Can be asymptomatic, but some develop isolated kidney stones, hypercalciuria, or mildly low bone density. |
| NPHLOP1 | Heterozygous SLC34A1 (One mutated copy) | Recurrent kidney stones, osteoporosis/osteomalacia, and hypophosphatemia, typically presenting later in life. |
| Infantile Hypercalcemia | Biallelic SLC34A1 (Two mutated copies) | Distinct severe presentation in infancy with hypercalcemia (high blood calcium) and nephrocalcinosis. |
What We Know About Treatment
The goal of treatment is to balance your minerals.
- Phosphate Supplementation: Taking oral phosphate multiple times a day is the standard care for significant phosphate wasting. It helps raise blood phosphate levels and signals your body to reduce active vitamin D production, which in turn lowers the calcium in your urine [1][9].
- The Vitamin D Warning: Unlike typical bone loss, confirmed HHRH should generally not be treated with active vitamin D analogs (like calcitriol). Taking more can worsen your urine calcium and accelerate kidney calcification [1]. Do not start or stop medications without consulting your specialist.
- Monitoring: Long-term care requires individualized checks of your blood phosphate, calcium, and PTH (parathyroid hormone), along with ultrasounds to watch for kidney calcification [11].
What Remains Uncertain
Because these conditions are so rare, there are still things experts are learning:
- Stone Prevention: While phosphate helps, it is not yet fully proven if it completely prevents new kidney stones or if additional medications (like specific diuretics) are needed for everyone [9][12].
- Bone Recovery: We know phosphate improves bone health, but long-term data is still being gathered on how well it prevents fractures over decades [1][11].
- Genetics: Sometimes, people have a “mix” of different gene variants that makes their symptoms more or less severe than expected [7].
Common questions in this guide
What are HHRH and NPHLOP1?
Could recurrent kidney stones and low bone density point to HHRH or NPHLOP1?
What tests help diagnose HHRH or NPHLOP1?
Can a DXA scan distinguish osteoporosis from osteomalacia?
Why might calcitriol be avoided in confirmed HHRH?
How is phosphate wasting from HHRH or NPHLOP1 treated and monitored?
Get notified when new evidence is published on nephrolithiasis/osteoporosis, hypophosphatemic.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.
Bergwitz C, Miyamoto KI
Pflugers Archiv : European journal of physiology 2019; (471(1)):149-163 doi:10.1007/s00424-018-2184-2.
PMID: 30109410 - 2
Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.
Gordon RJ, Li D, Doyle D, et al.
The Journal of clinical endocrinology and metabolism 2020; (105(7)) doi:10.1210/clinem/dgaa217.
PMID: 32311027 - 3
Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c.
Dhir G, Li D, Hakonarson H, Levine MA
Bone 2017; (97()):15-19 doi:10.1016/j.bone.2016.12.001.
PMID: 27939817 - 4
SLC34A3 Intronic Deletion in an Iranian Kindred with Hereditary Hypophosphatemic Rickets with Hypercalciuria
Hasani-Ranjbar S, Ejtahed HS, Amoli MM, et al.
Journal of clinical research in pediatric endocrinology 2018; (10(4)):343-349 doi:10.4274/jcrpe.0057.
PMID: 29809158 - 5
Late diagnosis of SLC34A3-related hereditary hypophosphatemic osteomalacia following a low-energy proximal humeral 4-part fracture.
Morimoto T
JBMR plus 2026; (10(10)):ziag137 doi:10.1093/jbmrpl/ziag137.
PMID: 42741772 - 6
Phosphate matters when investigating hypercalcemia: a mutation in SLC34A3 causing HHRH
Tang AR, Hinz LE, Khan A, Kline GA
Endocrinology, diabetes & metabolism case reports 2019; (2019(1)):1-6 doi:10.1530/EDM-19-0058.
PMID: 31352694 - 7
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review.
Walker E, Hayes W, Bockenhauer D
Best practice & research. Clinical endocrinology & metabolism 2024; (38(2)):101843 doi:10.1016/j.beem.2023.101843.
PMID: 38042745 - 8
Genu Valgum, Fractures, and Renal Stones in a 10-year-old Girl.
Christensen S, Loomba LA
JCEM case reports 2023; (1(1)):luac022 doi:10.1210/jcemcr/luac022.
PMID: 37908277 - 9
An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).
Zhu Z, Bo-Ran Ho B, Chen A, et al.
Kidney international 2024; (105(5)):1058-1076 doi:10.1016/j.kint.2024.01.031.
PMID: 38364990 - 10
Hereditary Hypophosphatemic Rickets with Hypercalciuria Presenting with Enthesopathy, Renal Cysts, and High Serum c-Terminal FGF23: Single-Center Experience and Systematic Review.
Dodamani MH, Memon SS, Karlekar M, et al.
Calcified tissue international 2024; (114(2)):137-146 doi:10.1007/s00223-023-01156-2.
PMID: 37981601 - 11
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187 - 12
Novel Variant of SLC34A3 in a Compound Heterozygous Brazilian Girl with Hereditary Hypophosphatemic Rickets with Hypercalciuria
Valadares LP, de Carvalho DR
Journal of clinical research in pediatric endocrinology 2025; (17(3)):326-331 doi:10.4274/jcrpe.galenos.2023.2023-5-2.
PMID: 37680384
This page explains HHRH and NPHLOP1 for informational purposes only and does not constitute medical advice. A qualified clinician should interpret your phosphate, bone, kidney, and genetic results before you change vitamin D, calcium, or phosphate treatment.